|1.||FEVER Study Group: 3 articles (06/2011 - 12/2005)|
|2.||Liu, Lisheng: 3 articles (06/2011 - 12/2005)|
|3.||Zhang, Xuezhong: 3 articles (06/2011 - 12/2005)|
|4.||Zanchetti, Alberto: 3 articles (06/2011 - 12/2005)|
|5.||Zhang, Yun: 3 articles (09/2008 - 01/2008)|
|6.||Zanchetti, A: 2 articles (06/2015 - 06/2015)|
|7.||Zhang, X: 2 articles (06/2015 - 06/2015)|
|8.||Zhang, Y: 2 articles (06/2015 - 06/2015)|
|9.||Liu, L: 2 articles (06/2015 - 06/2015)|
|10.||Zhao, Feng: 2 articles (01/2012 - 08/2010)|
|1.||Hypertension (High Blood Pressure)
01/01/1990 - "It is concluded that felodipine decreases BP dramatically in patients with previously refractory hypertension and that the drug causes an improved renal function in these patients."
11/18/2008 - "Slow releasing felodipine is effective in treating mild to moderate primary hypertension, with sustained efficacy of lowering blood pressure and PWV."
07/01/1996 - "Felodipine is effective in the treatment of elders with essential hypertension."
08/01/1995 - "These data suggest that once a day felodipine is effective in children with hypertension. "
12/01/1992 - "In conclusion, we found felodipine given once daily to be effective in the treatment of mild to moderate hypertension."
12/01/1989 - "In conclusion, felodipine was of benefit in congestive heart failure at rest in an acute test, acting through a marked decrease in vascular resistance and a consequent improvement in cardiac output and limb blood flow. "
11/01/1987 - "Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress."
01/01/1991 - "Acute and chronic efficacy of felodipine in congestive heart failure."
04/01/1989 - "Efficacy of felodipine in congestive heart failure."
11/01/1987 - "Thus three weeks treatment with felodipine improved haemodynamic function at rest and during standard exercise and normalised the baroreflex mediated haemodynamic response in patients with congestive heart failure. "
11/01/1991 - "The efficacy of felodipine in the management of chronic stable angina pectoris and CHF requires further investigation."
11/01/1991 - "Evaluations of patients with chronic stable angina are limited, and additional studies are needed before felodipine can be recommended for the routine management of angina pectoris. "
11/01/1995 - "Felodipine in addition to beta-adrenergic blockade for angina pectoris. "
08/15/1991 - "Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris."
01/01/1990 - "The effects of felodipine in angina pectoris."
07/01/1993 - "Mucosal hyperemia and tachycardia, as an expression of the vasodilating properties of felodipine, were observed in a somewhat variable but dose-related manner. "
05/01/1996 - "During 30 minutes of reperfusion, felodipine had a beneficial effect upon coronary blood flow (initial postischemic hyperemia 245 +/- 38% of baseline in the felodipine group vs. 124 +/- 18% in the controls; p < 0.01) Felodipine markedly improved the recovery of contractile function [LV developed pressure recovered from a baseline of 104 +/- 4 to 75 +/- 6 mmHg (72%) in the felodipine group vs. 34 +/- 10 mmHg (32%) in the control group; p < 0.01], as well as diastolic function (LVEDP = 25 +/- 4 mmHg in the felodipine group vs. 61 +/- 10 mmHg in the controls; p < 0.05), and ATP levels (8.5 +/- 1.4 mumoles/g d.w. "
01/20/2006 - "FBF during reactive hyperemia was significantly improved by candesartan in patients without HRT (hyperemic peak flow and area under the FBF curve), whereas felodipine and placebo exerted no effect. "
07/01/2002 - "FBF during reactive hyperemia was significantly improved by candesartan, whereas felodipine and placebo exerted no effect. "
07/01/2011 - "We examined the effects of ARB administration on hyperinsulinemia-associated capillary density by measuring baseline skin capillary density, capillary density during reactive hyperemia (hyperemic capillary recruitment), and capillary density during venous congestion in 17 hypertensive individuals in the basal state, during a hyperinsulinemic euglycemic clamp, and during a hyperinsulinemic clamp with acute ARB administration (600 mg irbesartan), acute calcium channel blockade (CCB; 10mg felodipine ER), as a control for the reduction in blood pressure, or placebo. "
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
11/01/2001 - "To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2.5, 5, or 10 mg once daily) and matching placebo was performed in 171 patients (49% male, average age 66+/-7 years, with 49% white and 30% Hispanic) with a baseline blood pressure of 149+/-7/83+/-6 mm Hg. During 52 weeks of treatment, patients randomized to active treatment achieved significantly lower blood pressures (137.0+/-11.7/80.2+/-7.6 mm Hg for extended-release felodipine versus 147.5+/-16.0/83.5+/-9.7 mm Hg for placebo, P<0.01 for each), a reduced incidence of left ventricular hypertrophy (7% for extended release felodipine versus 24% for placebo, P<0.04), and improved quality of life (change in Psychological General Well-Being index, 3.0+/-6.8 for extended-release felodipine versus -0.8+/-10.3 for placebo, P<0.01) versus baseline. "
11/01/1994 - "Clinical studies show that antihypertensive treatment with felodipine promotes regression of left ventricular hypertrophy, increases compliance of large arteries, and has favourable effects on renal function. "
08/01/1992 - "In addition to its antihypertensive action, results suggest that felodipine therapy is associated with significant regression of left ventricular hypertrophy. "
03/01/1992 - "Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy."
09/01/1996 - "The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension."
|9.||Calcium Channel Blockers (Blockers, Calcium Channel)
|3.||Transplantation (Transplant Recipients)
|4.||Surgical Instruments (Clip)